ライフサイエンスコーパス: escitalopram

1 randomized to sertraline, venlafaxine-XR, or escitalopram).

2 or bupropion to 0.83 [95% CI, 0.67-0.98] for escitalopram).

3 ponse to sertraline and venlafaxine, but not escitalopram.

4 nt selection in depression, particularly for escitalopram.

5 serotonin reuptake inhibitors fluoxetine and escitalopram.

6 s after 8 weeks of open-label treatment with escitalopram.

7 measures of executive function more than the escitalopram.

8 3 points higher with nortriptyline than with escitalopram.

9 ctions than historical controls treated with escitalopram.

10 ive behavior therapy, and 6 nonresponders to escitalopram.

11 reuptake inhibitors (SSRIs), sertraline and escitalopram.

12 a double-blind, randomized clinical trial of escitalopram.

13 by 1.35 (1.06) for MBSR and 1.43 (1.17) for escitalopram.

14 pression (CANBIND-1) RCT, which administered escitalopram.

15 in healthy humans following daily intake of escitalopram.

16 difference in the scores with placebo versus escitalopram.

17 ign with 8 wk of standardized treatment with escitalopram.

18 ed 8 wk of standardized pharmacotherapy with escitalopram.

19 r the selective serotonin reuptake inhibitor escitalopram.

20 subjects who completed phase 1 responded to escitalopram.

21 D-1) protocol received 8 weeks of open-label escitalopram.

22 s after 8 weeks of open-label treatment with escitalopram.

23 atin (40 mg per day) or placebo as add-on to escitalopram (10 mg for the first 2 weeks, then increase

24 ocybin, 3 weeks apart, plus 6 weeks of daily escitalopram (10-20 mg) ('escitalopram arm').

25 Patients were randomized 1:1 to receive escitalopram (10-20 mg) or matching placebo in addition

26 Among healthy women, the use of escitalopram (10-20 mg/d) compared with placebo resulted

27 igned to one of four conditions: 16 weeks of escitalopram (10-20 mg/day) plus modular CBT, followed b

28 ual likelihood to 12 weeks of treatment with escitalopram (10-20 mg/day), duloxetine (30-60 mg/day),

29 cale (HAM-D) score of 18 or greater received escitalopram, 10 mg daily, for 12 weeks.

30 Escitalopram, 10 mg/d (n = 90), or placebo (n = 91) admi

31 lop depression than individuals who received escitalopram (11 major and 2 minor cases of depression [

32 cantly differ between treatments (CBT: 10.2, escitalopram: 11.1, duloxetine: 11.2).

33 -week randomized placebo-controlled trial of escitalopram (15 mg/day, titrated to 20 mg/day).

34 we examined the effect of 3-5 weeks of SSRI escitalopram (20 mg daily) on brain response to angry, f

35 ompare nCCR-GD to a gold-standard treatment (escitalopram: 20 mg per 12 weeks) in 11 treatment-resist

36 At the end of 6 weeks, more patients taking escitalopram (34.2% [95% CI, 25.4%-43.0%]) had absence o

37 , 51 given amitriptyline (53%), and 37 given escitalopram (38%) (P = .05, after treatment, adjusted f

38 antly differ between treatments (CBT: 41.9%, escitalopram: 46.7%, duloxetine: 54.7%).

39 ADS-A (exercise, -4.0; 95% CI, -4.7 to -3.2; escitalopram, -5.7; 95% CI, -6.4 to -5.0) compared with

40 occurred for 110 participants randomized to escitalopram (78.6%) and 21 participants randomized to M

41 cognitive behavior therapy, 11 remitters to escitalopram, 9 nonresponders to cognitive behavior ther

42 ent randomization, with 91 being assigned to escitalopram, 94 to tDCS, and 60 to placebo.

43 lammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortri

44 n this study, we investigated the effects of escitalopram, a selective serotonin reuptake inhibitor (

45 essive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor,

46 In summary, early escitalopram administration could prevent the onset of s

47 Four weeks of escitalopram administration suppressed spastic behaviors

48 wed by 28 weeks of maintenance escitalopram; escitalopram alone, followed by maintenance escitalopram

49 pram plus CBT, followed by pill placebo; and escitalopram alone, followed by placebo.

50 Hamilton Anxiety Rating Scale compared with escitalopram alone.

51 Phase 2 relapse proportions were 18% for escitalopram and 40% for placebo.

52 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4 and 8 we

53 Both escitalopram and CBT prevented relapse compared with pla

54 ional 12 weeks of treatment with combination escitalopram and cognitive behavior therapy.

55 py (CBT) and two antidepressant medications (escitalopram and duloxetine) in patients with major depr

56 Both anxiety treatments (escitalopram and mindfulness-based stress reduction) red

57 cell states, which may enable repurposing of escitalopram and other drugs to limit cardiac remodeling

58 nce in mean cumulative response rate between escitalopram and placebo (57%; 95% CI, 46%-67%; vs 45%;

59 5% CI, 2.24-4.15) hot flashes per day in the escitalopram and placebo groups, respectively.

60 rmetabolism was associated with remission to escitalopram and poor response to cognitive behavior the

61 ith AG compared to brand-name initiation for escitalopram and sertraline (HR [95% CI]: 1.06 [0.98-1.1

62 the selective serotonin reuptake inhibitors escitalopram and sertraline and the serotonin-norepineph

63 Escitalopram and sertraline showed the best profile of a

64 the selective serotonin reuptake inhibitors escitalopram and sertraline than did A allele carriers.

65 For escitalopram and sertraline, we observed higher rates of

66 onded better and had fewer side effects with escitalopram and sertraline.

67 both efficacy and acceptability in favour of escitalopram and sertraline.

68 Escitalopram and tDCS were both superior to placebo (dif

69 Participants received 12 weeks of open-label escitalopram and were then randomly assigned to one of f

70 ric hospitalization rate (for sertraline and escitalopram), and insulin initiation (for glipizide) be

71 thiazines, fluoxetine, citalopram (including escitalopram), and methadone were significantly more fre

72 fluoxetine and cognitive behavioral therapy, escitalopram, and collaborative care demonstrated benefi

73 talopram than those treated with placebo and escitalopram, and median time to onset of anxiolytic res

74 Neither amitriptyline nor escitalopram appeared to affect GE or meal-induced satie

75 Amitriptyline, but not escitalopram, appears to benefit some patients with FD,

76 s 6 weeks of daily escitalopram (10-20 mg) ('escitalopram arm').

77 inicians need to be cautious in recommending escitalopram as an alternative to citalopram for this co

78 nt scores were improved with eszopiclone and escitalopram at every point (P < .02), while CGI of Seve

79 ask was correlated with clinical response to escitalopram at week 8. Early (baseline to week 2) incre

80 Escitalopram augmented with CBT increased response rates

81 wed the noninferiority of MBSR compared with escitalopram based on the improvement in CGI-S score.

82 tional enrichment analysis demonstrates that escitalopram-based remission associates to functions rel

83 d the serotonin selective reuptake inhibitor escitalopram both effectively restored DNIC after TBI in

84 s a randomized double-blind 12-week trial of escitalopram, bupropion, or the combination of the two i

85 med significantly above chance in a combined escitalopram-buproprion treatment group in COMED (n=134;

86 effective at reducing depressive symptoms as escitalopram but does so in 4 weeks instead of 12.

87 curacy specifically following treatment with escitalopram but not the other medications.

88 y outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked

89 y outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for mu

90 atments including psychotherapy, sertraline, escitalopram, citalopram, mirtazapine, duloxetine, trazo

91 For example, escitalopram/citalopram and diphenhydramine, taken orall

92 Remitters to escitalopram compared with escitalopram/memantine combin

93 and depression, 18 months of treatment with escitalopram compared with placebo did not significantly

94 the TPJ showed increased activity in IED on escitalopram compared with placebo.

95 heart disease and baseline MSIMI, 6 weeks of escitalopram, compared with placebo, resulted in a lower

96 , open-label nonrandomized clinical trial of escitalopram conducted at an outpatient geriatric psychi

97 whether pretreatment with the antidepressant escitalopram could reduce IL-2-induced neuroendocrine, i

98 CAN-BIND-1, patients received 10 to 20 mg of escitalopram daily; nonresponders at 8 weeks received ar

99 Continuation-phase escitalopram delayed time to relapse, and fewer escitalo

100 Ziprasidone as an adjunct to escitalopram demonstrated antidepressant efficacy in adu

101 Exercise and escitalopram did not improve CHD biomarkers of risk, whi

102 after treatment, while patients treated with escitalopram did not.

103 e difference in the decrease for tDCS versus escitalopram (difference, -2.3 points; 95% confidence in

104 participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20

105 ession who were randomly assigned to receive escitalopram, duloxetine, or CBT monotherapy and complet

106 l to achieve remission as a result of CBT or escitalopram, either alone or in combination, have a dis

107 Compared to placebo, escitalopram enhanced emotional processing speed and enh

108 placebo or the serotonin reuptake inhibitor, escitalopram (ESC) 10-20 mg/day, 2 weeks before, and dur

109 ersely, early exposure to the antidepressant escitalopram (ESC; Lexapro) results in decreased anxiety

110 bin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients rece

111 lar CBT, followed by 28 weeks of maintenance escitalopram; escitalopram alone, followed by maintenanc

112 escitalopram alone, followed by maintenance escitalopram; escitalopram plus CBT, followed by pill pl

113 the weekly MBSR course or the antidepressant escitalopram, flexibly dosed from 10 to 20 mg.

114 Furthermore, escitalopram, fluoxetine, and cocaine induced a very sim

115 n adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirt

116 pram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefaz

117 onin reuptake inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), v

118 given placebo, 50 mg amitriptyline, or 10 mg escitalopram for 10 weeks.

119 body dysmorphic disorder received open-label escitalopram for 14 weeks (phase 1); 58 responders were

120 trial of psilocybin therapy versus an SSRI, escitalopram, for depression.

121 proaches such as citalopram, desvenlafaxine, escitalopram, gabapentin, paroxetine, and venlafaxine ar

122 ividuals treated with citalopram (STAR*D) or escitalopram (GENDEP) identified an intergenic region on

123 ity scores were significantly greater in the escitalopram group (-0.52; 95% CI, -0.64 to -0.40 vs -0.

124 chemia were slightly lower at 6 weeks in the escitalopram group (45.8% [95% CI, 36.6%-55.0%]) than in

125 cantly among those whose mothers were in the escitalopram group (compared with those whose mothers we

126 pation time of 18.4 months (n = 185) for the escitalopram group and 18.7 months (n = 187) for the pla

127 n was diagnosed in 8% of the patients in the escitalopram group and 19% in the placebo group (absolut

128 20.2 at baseline to 11.2 at 12 weeks in the escitalopram group and from 21.4 to 12.5 in the placebo

129 tarted treatment, 10 (8%) dropped out of the escitalopram group and none from the MBSR group due to a

130 4.93; P = .01) and greater reductions in the escitalopram group compared with the exercise group (F1,

131 greater reductions in the exercise group and escitalopram group compared with the placebo group (F1,1

132 (95% CI, 21% to 43%) of the patients in the escitalopram group developed a MADRS score of 13 or high

133 ) for the MBSR group and 4.51 (0.78) for the escitalopram group in the per-protocol sample and 4.49 (

134 Participants in the escitalopram group produced more effort and thereby achi

135 ee weeks after treatment ended, women in the escitalopram group reported a mean 1.59 (95% CI, 0.55-2.

136 cipants randomized to the exercise group and escitalopram group reported greater reductions in HADS-A

137 nges in parental functioning: Mothers in the escitalopram group reported significantly greater improv

138 Fifty-five percent of women in the escitalopram group vs 36% in the placebo group reported

139 Only in the escitalopram group was significant improvement of mother

140 art plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psycholog

141 ore (P < .01, adjusted mean change in score: escitalopram group, 10.0; nonescitalopram group, 3.1) an

142 ore (P < .01, adjusted mean change in score: escitalopram group, 11.3; nonescitalopram group, 2.5).

143 In the escitalopram group, 56% (CI, 46% to 66%) of patients ach

144 e from baseline was 11.3+/-6.5 points in the escitalopram group, 9.0+/-7.1 points in the tDCS group,

145 eduction of response to fearful faces in the escitalopram group, but lesser effects for the psilocybi

146 psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22

147 all types were significantly reduced in the escitalopram group, with no change or a slight increase

148 signed to the psilocybin group and 29 to the escitalopram group.

149 tly only for those whose mothers were in the escitalopram group.

150 Remitters to escitalopram had 33% higher baseline 5-HT1A binding in t

151 Older adults with GAD randomized to escitalopram had a higher cumulative response rate for i

152 Patients taking eszopiclone and escitalopram had greater improvements in total Hamilton

153 Patients receiving escitalopram had more frequent sleepiness and obstipatio

154 ases showed that patients with depression on escitalopram have a lower incidence of cardiac hypertrop

155 s previously reported to predict response to escitalopram in a sample different from the current stud

156 ntidepressant effects between psilocybin and escitalopram in a selected group of patients.

157 domised controlled trials on psychedelics or escitalopram in adults with depressive symptoms.

158 These findings do not support the use of escitalopram in patients with chronic systolic heart fai

159 rial, we assessed the efficacy and safety of escitalopram in treating agitation in AD after failure o

160 r example, high-dose duloxetine outperformed escitalopram in treating core emotional symptoms (effect

161 ude that nCCR-GD may be equally effective as escitalopram in treating GD.

162 responded differently to the application of escitalopram in vitro.

163 Escitalopram increased amygdala activation in controls,

164 Baseline amygdala-vmPFC connectivity and escitalopram-induced increased amygdala-angular gyrus co

165 ake inhibitors (SSRIs) such as fluoxetine or escitalopram inhibit SERT and are currently the principa

166 Patient group (psilocybin versus escitalopram) interacted with time point (before versus

167 itors of monoamine transporters (reboxetine, escitalopram, JHW-007) whereas its effects on the length

168 ental cardiovascular effects than sertraline/escitalopram (large ES); antidepressants were neutral on

169 xine (MD -2.69, 95% CrI -3.50 to -1.89), and escitalopram (MD -2.45, 95% CrI -3.27 to -1.63) were mor

170 lower than that in antidepression trials of escitalopram (mean difference -3.90 (95% credible interv

171 ter than placebo in antidepression trials of escitalopram (mean difference 6.45 (3.19 to 9.41)).

172 onnaires, neuropsychological tests and serum escitalopram measures were taken.

173 Remitters to escitalopram compared with escitalopram/memantine combination treatment display uni

174 placebo-controlled trial of escitalopram or escitalopram/memantine in late-life depression with subj

175 Escitalopram/memantine-based remission, however, is char

176 to receive daily oral dosing of either 20 mg escitalopram (n = 17) or a placebo (n = 15).

177 data analysis sample received treatment with escitalopram (n = 22) or duloxetine (n = 14) for 10 week

178 ouble-blind placebo-controlled comparison of escitalopram (n = 43) with placebo (n = 45), and a nonbl

179 ouble-blind placebo-controlled comparison of escitalopram (n = 59) with placebo (n = 58), and a nonbl

180 Of 127 participants randomized to receive escitalopram (n = 64) or placebo (n = 63), 112 (88.2%) c

181 Twelve weeks of 10 to 20 mg/d of escitalopram (n = 85) or matching placebo (n = 92).

182 randomly allocated to 12-week treatment with escitalopram (N=115) or nortriptyline (N=126).

183 n ancestry treated for major depression with escitalopram (N=394) or nortriptyline (N=312) over a 12-

184 gness was associated with poorer efficacy of escitalopram (odds ratio [OR] = 1.04; 95% CI, 1.02 to 1.

185 80% (from 78.6% for odansetron to 93.9% for escitalopram) of study drug new-use prescriptions occurr

186 used to investigate the treatment effect of escitalopram on amygdala connectivity.

187 e have been no studies of chronic effects of escitalopram on cognition in healthy volunteers.

188 Here, we investigate the effects of the SSRI escitalopram on presynaptic density as a proxy for synap

189 investigate the chronic effect of the SSRI, escitalopram, on measures of 'cold' cognition (including

190 Women received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.

191 with a 2-way analysis of variance treatment (escitalopram or cognitive behavior therapy) x outcome (r

192 ressive disorder and were assigned to either escitalopram or cognitive behavioral therapy based on fl

193 ssigned to 12 weeks of treatment with either escitalopram or cognitive-behavioral therapy (CBT).

194 - and male-identifying patients treated with escitalopram or desvenlafaxine and assessed for treatmen

195 ind, randomized, placebo-controlled trial of escitalopram or escitalopram/memantine in late-life depr

196 ived randomized 8-week treatment with either escitalopram or mindfulness-based stress reduction.

197 ssociated with the outcome of treatment with escitalopram or nortriptyline at suggestive levels of si

198 iagnosis of GAD randomized to receive either escitalopram or placebo and conducted between January 20

199 ssed patients with recent stroke, the use of escitalopram or problem-solving therapy resulted in a si

200 umulate within lipid membranes by >=18-fold (escitalopram) or 180-fold (fluoxetine), and possibly by

201 ent with cognitive behavioral therapy (CBT), escitalopram, or duloxetine for major depressive disorde

202 ceive tDCS plus oral placebo, sham tDCS plus escitalopram, or sham tDCS plus oral placebo.

203 ts who achieve remission as a result of CBT, escitalopram, or their combination.

204 of depression did not show noninferiority to escitalopram over a 10-week period and was associated wi

205 ignment to 12 weeks of treatment with either escitalopram oxalate (10-20 mg/d) or 16 sessions of manu

206 % CI, 1.28-1.44; 23 studies; 1492 patients), escitalopram oxalate (CYP2C19 PM vs NM, RoM, 2.63; 95% C

207 y prior to treatment randomization to either escitalopram oxalate or cognitive behavior therapy for 1

208 pram hydrobromide, duloxetine hydrochloride, escitalopram oxalate, fluoxetine hydrochloride, mirtazap

209 ted with the FDA-approved drugs tramadol and escitalopram oxalate, they release or uptake serotonin i

210 Patients received 10 mg of escitalopram oxolate for 10 weeks and were randomized to

211 flashes per day at week 8 among women taking escitalopram (P < .001), with mean reductions of 4.60 (9

212 Adverse effects of escitalopram (P < .05 vs placebo) were fatigue or somnol

213 potential for hepatotoxicity are citalopram, escitalopram, paroxetine, and fluvoxamine.

214 pression after an 8-week open-label trial of escitalopram (phase 1), randomly assigned in a 1:1 ratio

215 alone, followed by maintenance escitalopram; escitalopram plus CBT, followed by pill placebo; and esc

216 were treated with an additional 12 weeks of escitalopram plus CBT.

217 se of intolerance, compared with none in the escitalopram plus placebo group.

218 us ziprasidone, N=71) or adjunctive placebo (escitalopram plus placebo, N=68), with 8 weekly follow-u

219 =21; 6 women and 15 men) received 6 weeks of escitalopram plus two dosing sessions with a nonpsychoac

220 The escitalopram plus ziprasidone group also showed signific

221 Ten (14%) patients in the escitalopram plus ziprasidone group discontinued treatme

222 [SD=6.2]) were significantly greater for the escitalopram plus ziprasidone group.

223 1:1 ratio to receive adjunctive ziprasidone (escitalopram plus ziprasidone, N=71) or adjunctive place

224 reuptake inhibitors (SSRIs), citalopram and escitalopram prolong the QT interval to the greatest ext

225 Among individual SSRIs, sertraline and escitalopram provided high remission with an acceptable

226 Further, escitalopram reduced cardiomyocyte hypertrophy in a mous

227 e, phenothiazines, and citalopram (including escitalopram) remained statistically significant.

228 ects then received 8 weeks of treatment with escitalopram; remission was defined as a posttreatment 2

229 o -2.4; P = .03); participants randomized to escitalopram reported less anxiety compared with those r

230 Escitalopram response is associated with clinical and ne

231 escitalopram, treatment with eszopiclone and escitalopram resulted in significantly improved sleep an

232 enzofuran-5-carboni trile), and its eutomer, escitalopram (S-(+)-1) are selective serotonin reuptake

233 Here we showed that n-3 PUFAs and escitalopram (selective serotonin reuptake inhibitors, S

234 Participants were randomized to 1 of 3 arms: escitalopram, sertraline (serotonin-specific reuptake in

235 eks of randomized open-label treatment ADMs: escitalopram, sertraline or venlafaxine-extended release

236 Patients were randomized to escitalopram, sertraline or venlafaxine-XR antidepressan

237 mes for three commonly used antidepressants (escitalopram, sertraline, and extended-release venlafaxi

238 ndomly assigned to 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxin

239 whom 576 completed 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxin

240 the selective serotonin reuptake inhibitors escitalopram, sertraline, or fluoxetine may be prescribe

241 ive disorder (n = 124) randomized to receive escitalopram, sertraline, or venlafaxine (8 weeks) and h

242 1:1:1 ratio to antidepressant treatment with escitalopram, sertraline, or venlafaxine extended-releas

243 ment with one of three antidepressant drugs (escitalopram, sertraline, or venlafaxine extended-releas

244 pressed participants were then randomized to escitalopram, sertraline, or venlafaxine-extended releas

245 Participants treated with escitalopram showed greater improvement than with placeb

246 olving Therapy, stroke patients who received escitalopram showed improvement in global cognitive func

247 iority margin of -2.75 (50% of placebo minus escitalopram), so noninferiority could not be claimed.

248 Mental Stress-Induced Myocardial Ischemia to Escitalopram) study underwent psychometric assessments,

249 rial (Treatments for Anxiety: Meditation and Escitalopram [TAME]) included a noninferiority design wi

250 her in patients treated with eszopiclone and escitalopram than those treated with placebo and escital

251 on the MADRS score was 3 points higher with escitalopram than with nortriptyline.

252 ime to relapse was significantly longer with escitalopram than with placebo treatment (hazard ratio=2

253 Escitalopram, the S-enantiomer, may be an alternative.

254 h the selective serotonin reuptake inhibitor escitalopram; this is consistent with data from a separa

255 2-week washout period, participants received escitalopram titrated to a target of 20 mg/d for 12 week

256 S-induced histamine increase, the ability of escitalopram to augment extracellular serotonin is impai

257 in histamine synthesis boosts the ability of escitalopram to increase extracellular serotonin levels

258 impaired because of an off-target action of escitalopram to inhibit histamine reuptake.

259 owing acute response; more than one-third of escitalopram-treated subjects experienced further improv

260 italopram delayed time to relapse, and fewer escitalopram-treated subjects relapsed than did placebo-

261 Among escitalopram-treated subjects, body dysmorphic disorder

262 ants received an 8-week treatment regimen of escitalopram treatment (10-20 mg), and EMBARC participan

263 (Responses of Myocardial Ischemia to Escitalopram Treatment [REMIT]; NCT00574847).

264 antly improved during 6 additional months of escitalopram treatment following acute response; more th

265 We externally validated the model in the escitalopram treatment group (n=151) of an independent c

266 The model was externally validated in the escitalopram treatment group (N=151) of COMED (accuracy

267 ith treatment outcome following standardized escitalopram treatment in MDD.

268 nfounders, there was a significant effect of escitalopram treatment on the change in RBANS total scor

269 l biomarker for remission after standardized escitalopram treatment.

270 Compared with treatment with placebo and escitalopram, treatment with eszopiclone and escitalopra

271 PSI non-responders received escitalopram (up to 15 mg per day) or placebo for 12 wee

272 Mirtazapine, escitalopram, venlafaxine, and sertraline were significa

273 total, 173 participants were randomized (84 escitalopram versus 89 placebo; mean +/- s.d. age = 78.4

274 to double-blind continuation treatment with escitalopram versus switch to placebo for 6 months (phas

275 for prolonging the QT interval (citalopram, escitalopram) versus the risk among those initiating SSR

276 f dropout, mean cumulative response rate for escitalopram was 69% (95% confidence interval [CI], 58%-

277 ents who did not achieve remission with CBT, escitalopram was added (CBT plus medication group) to th

278 Response to escitalopram was associated with significantly lower sel

279 Initiation with escitalopram was associated with the greatest risk reduc

280 Response to escitalopram was best predicted by a marker in the inter

281 Noninferiority of tDCS versus escitalopram was defined by a lower boundary of the conf

282 e level, but an association with response to escitalopram was detected in the interleukin-6 gene, whi

283 Prophylactic antidepressant treatment with escitalopram was effective in reducing the incidence and

284 Escitalopram was given at a dose of 10 mg per day for 3

285 This beneficial effect of escitalopram was independent of its effect on depression

286 randomized sample was smaller than planned, escitalopram was not effective in treating agitation in

287 8 weeks, 95% CI, 1.6 to 3.1; P < .001), but escitalopram was not significantly different from placeb

288 A significant difference favoring escitalopram was observed (odds ratio, 2.62 [95% CI, 1.0

289 rolling for prior history of mood disorders, escitalopram was superior to placebo (23.1% vs 34.5%; ad

290 Coadministration of eszopiclone and escitalopram was well tolerated and associated with sign

291 Among SSRIs, sertraline and escitalopram were associated with high remission and low

292 5-HT levels before and after treatment with escitalopram were dose-dependent and variable across pat

293 nausea, and adverse effects associated with escitalopram were not significantly different between th

294 thcognitive behavior therapy, duloxetine, or escitalopram were prospectively monitored for up to 21 m

295 els of hippocampal 5HT; however responses to escitalopram were significantly impaired in the hippocam

296 humans given a single dose of an SSRI (20 mg escitalopram), which can decrease post-synaptic serotoni

297 nitive behavior therapy and poor response to escitalopram, while insula hypermetabolism was associate

298 We expected that escitalopram would reduce amygdala activity in IED and i

299 We hypothesized that patients who received escitalopram would show improved performance in neuropsy

300 xercise z score = 0.05; 95% CI, -0.2 to 0.3; escitalopram z score = -0.24; 95% CI, -0.4 to 0; placebo